Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
about
Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case seriesSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-Cancer Drug Testing in 3D CultureGemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.Combination chemotherapy with mitomycin C and methotrexate is active against metastatic HER2-negative breast cancer even after treatment with anthracycline, taxane, capecitabine, and vinorelbine.A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.A comparison of toxicity profiles between the lower and standard dose capecitabine in breast cancer: a systematic review and meta-analysis.Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxaneCapecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilonePooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.Factors responsible for long-term survival in metastatic breast cancer.Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyCapecitabine: fulfilling the promise of oral chemotherapy.Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving CapecitabineProphylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.Phase II study of Pseudomonas aeruginosa-Mannose-Sensitive hemagglutinin in combination with capecitabine for Her-2-negative metastatic breast cancer pretreated with anthracycline and taxane.Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Response of cutaneous metastases from breast cancer to capecitabine.Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility StudyPhase II multi-center clinical study on using S-1 to treat advanced breast cancer after resistance to anthracycline and taxane drugs in Chinese patientsOptimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling.Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer.Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer.Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancerA phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomasCurrent approaches to the management of Her2-negative metastatic breast cancer.Taxanes for the treatment of metastatic breast cancer.Second-line treatment of postmenopausal women with advanced breast carcinoma.Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.
P2860
Q27015875-B4408839-A27F-4064-BB19-B1459B4FFCEAQ28080469-8F958A57-B1B4-4A83-8F9D-802701E0F828Q30317067-FBC94997-4B42-4BDF-B2E9-59F6CCCDD2DAQ30403638-7B53819A-0187-4D0B-923B-17A1377AD027Q33378298-19EFA8F9-52B4-4566-B2F1-9BAD196CCDACQ33382437-BB1001EC-23FB-412E-B0D6-58BC02A5750EQ33421880-2E7D59B5-99EF-4ED2-BC88-43BB795D0C05Q33424774-4E514094-22FF-46CF-80BE-5DBBD8EB2217Q33430668-27F442AD-DA03-4E8A-A8C1-284326B01800Q33430813-E8EA0B2C-41F7-431C-A45F-768DE1260204Q33990883-973721CD-9E6D-4DAB-A1C4-FB4B54802CA3Q34096083-4E1EF62F-2A3A-461C-AD9E-767C9DECEFEBQ34274930-9E2D9EB2-999E-43C7-BA94-11F0404B8D27Q34458907-CE0F2C36-33A9-416E-B550-C0AC345B1FF6Q34488678-5C52F72F-4089-4F20-B3B7-98932C1589FAQ34537146-92ADA730-8E59-463F-AAE8-C9F649216B8EQ34658293-18305DAD-2282-4A5A-A81E-DF80E10D809DQ34660785-AA08155D-FBDE-4F73-B5C1-CA060F0AF8B8Q34791173-D8E909E1-FE94-429B-9B67-157A51AD0D28Q35125646-E63284D8-F15D-45FA-A746-C53192E15726Q35175762-95075BE1-E65B-4766-BD58-AE4A678DB1FAQ35180940-10B349CA-DDFA-473E-AD1F-1F3BEC2200DCQ35180944-2E362010-F70F-4B5D-8B05-8AF409FFDF12Q35180995-17E46CB3-C469-43EF-BF33-AC7CFF0B716CQ35482173-266268A0-F31C-4E02-9F56-3F885E79417EQ35585064-27183746-CE78-4B20-9CD9-C327CF2C80A1Q35599745-67BB6D69-06AB-4080-BAF7-2BEE92DA3755Q35736115-C45D162F-9B37-447B-A65B-9F86F96CB4ADQ35776220-713980FF-D16B-4EF2-9E27-4C543B187A4CQ35871180-32E28CFE-B0CD-4381-89C0-392D411CE1AFQ35872691-03AC597B-7565-4734-9EA6-BF8D2A61ECA0Q36083065-D89D6851-602C-4EAC-8913-C75FE246A999Q36132957-FDA84735-BE46-4491-A68A-D5154BB80304Q36151475-6E0F306C-0F28-4829-8C5E-7D4491642F24Q36195618-E356D639-7D96-4526-B725-BD890AA07DBBQ36201411-4A623D44-C114-4723-A971-5C21F5F4E099Q36245461-11B49ECD-9E21-44C6-BD7E-EE6051990733Q36364762-38F36AA5-99F5-40A8-BF02-E8E4DCFC79EBQ36448699-B5A98799-C4CD-4E96-A856-2241EBE46CD6Q36506987-AB81EFA7-AD55-4C55-BB30-20AE99AE4F56
P2860
Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@en
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@nl
type
label
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@en
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@nl
prefLabel
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@en
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@nl
P2093
P2860
P1433
P1476
Multicenter, Phase II study of ...... tic breast carcinoma patients.
@en
P2093
B Osterwalder
P M Lo Russo
P2860
P304
P356
10.1002/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A
P407
P577
2001-10-01T00:00:00Z